iHealth products actively explore promotion models and profit models. The iHealth product line is becoming more and more diverse, covering many signs such as blood pressure, blood sugar, body weight, and fetal heart. In the future, it may enter fields such as breathing and biochemical diagnosis. Also, there are upgraded products for mother and child monitoring (ibabymonitor). The mobile medical market has huge potential for development. Companies started early, but there are more and more competitors. Judging from now on, the company has a leading edge in product diversity, software development, manufacturing, platform building, and brand promotion. This field is on the rise, and the product promotion model and profit model are still unclear. Jiu'an is also actively experimenting with cooperation with various participants such as hospitals, doctors, insurance, etc., and is looking forward to exploring a smooth product sales path and profit model. Taking a step back, even if iHealth can't be a trendsetter, it can become a quick follower in the industry. It is estimated that iHealth products will sell 10 million US dollars in 2013 and exceed 20 million US dollars in 2014. Domestic sales of Jiu'an blood pressure and blood sugar products continued to grow at a high rate. The increase in domestic sales is another major focus of the company's business. Jiu'an blood pressure monitor has become the number one selling brand of blood pressure monitors in JD. Starting with ODM, the company is significantly higher than other similar enterprises in terms of cost control and manufacturing process, so it has more price space to occupy the market. Benefiting from the growth of online business and the increase in sales categories, the domestic business maintained high growth in 2013, with an estimated revenue of 160 million yuan and expected to reach 250 million yuan in 2014, which is in line with the export business, achieving the strategic goal of “turning domestic into foreign”. The strategic position of the traditional ODM business declined. Since iHealth products are in the promotion stage and the domestic market volume is relatively small, the traditional ODM business is still the main source of the company's current revenue and profit. The company's revenue and profit over the past two years have been greatly affected by the reduction in traditional European business orders, rising costs, and higher personnel costs. The situation will improve in 2014, and the number of orders is expected to increase by 10%. Judging from the strategic position, the traditional business is no longer the focus of the company's development; it is just a business that provides cash flow. In future development, its position will gradually decline. Conclusion: The company's current sales scale and market value are not large, but there is a lot of room for development, and the company has the potential to grow bigger and stronger in terms of management, products, and marketing. The next few years will be in a period of rapid development and growth. Therefore, although from the perspective of PE, the company's stock price cannot be considered very “cheap,” the surprise that exceeds expectations from time to time during this growth process will make investors feel that it is “worth the money.” Maintain the company's profit forecasts of 0.03 yuan and 0.11 yuan for 2013-2014, and maintain a highly recommended rating. Risk warning: the risk that new products will not progress as expected; the risk that costs will rise sharply; the risk that exchange losses will increase; the risk that gross margin will decrease due to rising raw material prices; and the risk that shareholders' holdings will be reduced due to the lifting of the ban on some restricted stocks.